Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2019

View Archived Issues

Aspartylglycosamine as a potential new biochemical marker of NGLY1-CDDG

Imotope shows promise in EAE model

Methylation patterns, AI identify metastases

Mitochondria differ between cell types

EGPI-1 as a promising new anticancer agent that targets the eIF4E/eIF4G interface

p38Gamma as a novel therapeutic target in human colorectal cancer

Waking up sleeping Xs

Enrollment initiated in phase III study of NmCV-5

First volunteers dosed in phase I clinical program of IMU-935

Results presented from AFIRE study of rivaroxaban monotherapy versus combination therapy

Identification of a novel Mtb inhibitor BRD-8000.3 through large-scale chemical-genetics platform

Sichuan University reports phase I results for yogliptin

D-578 demonstrates antidepressant and anti-PTSD-like effects in vivo

Study finds microbe drives CRC, identifies therapeutic target

First-in-human study evaluates UB-312 in healthy subjects and patients with Parkinson's disease

Heidelberg Pharma's work in ETN MAGICBULLET project supported by new E.U. grant

Molecular Templates begins first-in-human study of MT-5111 in HER2-positive solid tumors

U.S. researchers patent HLA DQ8 ligands

SciFluor Life Sciences presents new integrin receptor antagonists

Genentech identifies new SCN9A blockers

Karus Therapeutics describes HDAC inhibitors

New cytokine biosynthesis inducers presented by 3M Pharmaceuticals

Onxeo reports initial data from first part of phase Ib DRIIV study of AsiDNA

Alzprotect cleared to begin French phase IIa trial of AZP-2006 in progressive supranuclear palsy

BeiGene studies BGB-A1217 with tislelizumab in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...